Abstract
Dermatomycoses are among the most widespread and common superficial and cutaneous fungal infections in humans. These typically nonfatal conditions are difficult to treat, especially infections of the nail. Dermatomycoses are caused by filamentous fungi such as Trichophyton, Microsporum or Epidermophyton species. These filamentous fungi have a high affinity for keratin, an important component of hair, skin and nails, which are the primary areas of infection by dermatophytes. The antifungal agents currently marketed for dermatomycoses are mainly inhibitors of ergosterol biosynthesis, except for griseofulvin, which interferes with the cytoplasmic and nuclear microtubular system. Three different types of inhibitors of the ergosterol biosynthetic pathway have been proven to be effective in clinic: the azoles (e.g. topical miconazole and topical/oral ketoconazole, itraconazole and fluconazole), the allylamines (e.g. terbinafine) and morpholines (amorolfine). Even today more effective antifungal azoles with less adverse effects and short-term therapy are deemed necessary to treat dermatophytosis. A promising novel triazole compound in this respect is R126638, which showed potent in vitro and in vivo activity.
Keywords: dermatomycoses, dermatophytes, yeasts, antifungals, skin kinetics, prevention, resistance, pulse therapy
Current Drug Targets
Title: Fungal Infections of the Skin: Infection Process and Antimycotic Therapy
Volume: 6 Issue: 8
Author(s): M. Borgers, H. Degreef and G. Cauwenbergh
Affiliation:
Keywords: dermatomycoses, dermatophytes, yeasts, antifungals, skin kinetics, prevention, resistance, pulse therapy
Abstract: Dermatomycoses are among the most widespread and common superficial and cutaneous fungal infections in humans. These typically nonfatal conditions are difficult to treat, especially infections of the nail. Dermatomycoses are caused by filamentous fungi such as Trichophyton, Microsporum or Epidermophyton species. These filamentous fungi have a high affinity for keratin, an important component of hair, skin and nails, which are the primary areas of infection by dermatophytes. The antifungal agents currently marketed for dermatomycoses are mainly inhibitors of ergosterol biosynthesis, except for griseofulvin, which interferes with the cytoplasmic and nuclear microtubular system. Three different types of inhibitors of the ergosterol biosynthetic pathway have been proven to be effective in clinic: the azoles (e.g. topical miconazole and topical/oral ketoconazole, itraconazole and fluconazole), the allylamines (e.g. terbinafine) and morpholines (amorolfine). Even today more effective antifungal azoles with less adverse effects and short-term therapy are deemed necessary to treat dermatophytosis. A promising novel triazole compound in this respect is R126638, which showed potent in vitro and in vivo activity.
Export Options
About this article
Cite this article as:
Borgers M., Degreef H. and Cauwenbergh G., Fungal Infections of the Skin: Infection Process and Antimycotic Therapy, Current Drug Targets 2005; 6 (8) . https://dx.doi.org/10.2174/138945005774912726
DOI https://dx.doi.org/10.2174/138945005774912726 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview of the Pharmacological Properties and Potential Applications of Natural Monoterpenes
Mini-Reviews in Medicinal Chemistry Post-Translational Modification of Transcription Factors: Mechanisms and Potential Therapeutic Interventions
Current Molecular Pharmacology Involvement of Regulatory T Cells in HIV Immunopathogenesis
Current HIV Research Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Haptoglobin Polymorphisms and Fucosylation Change: Possible Influence of Variation on the Identified Lung Cancer-relevant Biomarkers
Current Proteomics Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency
Current Pharmaceutical Design IL-1β and IL-1Ra Variant Profiles in Turkish Patients with Diabetic Peripheral Neuropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
Current Drug Targets Subject Index
Current Signal Transduction Therapy Preface
Current Pharmaceutical Design Synthesis and Anti-Cancer Activities of Aryl Benzyl Ethers with Fluoro Substituents
Letters in Drug Design & Discovery NF-κB Signaling: Multiple Angles to Target OA
Current Drug Targets Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Cytotoxic Effects and Production of Cytokines Induced by the Endophytic Paenibacillus polymyxa RNC-D In Vitro
Current Pharmaceutical Biotechnology Autoantibodies Among HIV-1 Infected Individuals and the Effect of Anti-Retroviral Therapy (ART) on It
Current HIV Research Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Microglial Activation and its Implications in the Brain Diseases
Current Medicinal Chemistry Effect of Thermal and Shear Stressors on the Physical Properties, Structural Integrity and Biological Activity of the Anti-TNF-alpha Monoclonal Antibody, Infliximab
Current Pharmaceutical Biotechnology Recent Progress in the Development of Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase
Current Topics in Medicinal Chemistry